Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies

Study Summary

The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Interventions

Study Locations

Facility	City	State	Country
Zhujiang Hospital of Southern Medical University	Guangzhou	Guangdong	China
Zhujiang Hospital of Southern Medical University	Guangzhou	Guangdong	China
Shenzhen Geno-immune Medical Institute	Shenzhen	Guangdong	China
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center	Kunming	Yunnan	China

Official Trial Information

View on ClinicalTrials.gov